Korean Diabetes J.  2009 Apr;33(2):113-123. 10.4093/kdj.2009.33.2.113.

Matrix Metalloproteinase-3 Gene Polymorphism is Associated with Coronary Artery Calcification Scores in Patients with Type 2 Diabetes Mellitus

• Kim SW
• Cho EH

• KMID: 2298068
• DOI: http://doi.org/10.4093/kdj.2009.33.2.113

Abstract

BACKGROUND
Matrix metalloproteinase-3 (MMP-3) is expressed in human coronary atherosclerotic lesions and is known to be involved in the degradation of plaque. This study examines the association of MMP-3 gene promoter 5A/6A and -709A>G polymorphisms with coronary artery calcium scores in type 2 diabetes patients. METHODS: The study comprises 140 type 2 diabetes patients aged 34~85 years, who showed no evidence of clinical cardiovascular disease before recruitment. Recruitment was based on patient's coronary artery calcium (CAC) scores and polymorphisms were identified. RESULTS: Multiple regression analysis showed that the CAC scores were significantly associated with age (P = 0.008), waist circumference (P = 0.03), duration of diabetes (P = 0.003) and the serum creatinine level (P = 0.012). MMP-3 5A/6A and -709A>G polymorphisms were not associated with CAC across all subjects. However, in the subgroup with a duration of diabetes over 10 years, MMP-3 -709A>G were significantly associated with CAC (P = 0.037) adjusted for age, body mass index, waist circumference and duration of diabetes. CONCLUSION: Our data suggest that the CAC scores in patients with type 2 diabetes were related with age, waist circumference, duration of diabetes and higher serum creatinine levels. MMP-3 polymorphisms with -709A>G are associated with high CAC in patients with a duration of diabetes over 10 years.

Keyword

Coronary vessels; Genetic polymorphism; Matrix metalloproteinase 3; Calcinosis

MeSH Terms

Aged
Body Mass Index
Calcinosis
Calcium
Cardiovascular Diseases
Coronary Vessels
Creatinine
Diabetes Mellitus, Type 2
Humans
Matrix Metalloproteinase 3
Polymorphism, Genetic
Waist Circumference
Calcium
Creatinine
Matrix Metalloproteinase 3

Figure

• 

  Fig. 1 Box plot showing coronary artery calcification score (CACs) both in 75 subjects with the duration of diabetes less than 10 years (blank box) and in 65 subjects with the duration of diabetes more than 10 years (dashed box) according to matrix metalloproteinase-3 (MMP-3) gene -709A>G polymorphisms adjusted with age, body mass index, waist circumference and duration of diabetes (*P value = 0.037).

Reference

1. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995. 91:2844–2850.

2. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, Humphries S. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A. 1991. 88:8154–8158.

3. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994. 94:2493–2503.

4. Bini A, Mann KG, Kudryk BJ, Schoen FJ. Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1999. 19:1852–1861.

5. Silence J, Lupu F, Collen D, Lijnen HR. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (mmp-3) gene inactivation. Arterioscler Thromb Vasc Biol. 2001. 21:1440–1445.

6. Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem. 1996. 271:13055–13060.

7. Humphries SE, Luong LA, Talmud PJ, Frick MH, Kesaniemi YA, Pasternack A, Taskinen MR, Syvanne M. The 5a/6a polymorphism in the promoter of the stromelysin-1 (mmp-3) gene predicts progression of angiographically determined coronary artery disease in men in the locat gemfibrozil study. Lopid coronary angiography trial. Atherosclerosis. 1998. 139:49–56.

8. de Maat MP, Jukema JW, Ye S, Zwinderman AH, Moghaddam PH, Beekman M, Kastelein JJ, van Boven AJ, Bruschke AV, Humphries SE, Kluft C, Henney AM. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol. 1999. 83:852–856.

9. Traurig MT, Permana PA, Nair S, Kobes S, Bogardus C, Baier LJ. Differential expression of matrix metalloproteinase 3 (mmp3) in preadipocytes/stromal vascular cells from nonobese nondiabetic versus obese nondiabetic pima indians. Diabetes. 2006. 55:3160–3165.

10. Kaplan RC, Smith NL, Zucker S, Heckbert SR, Rice K, Psaty BM. Matrix metalloproteinase-3 (mmp3) and mmp9 genes and risk of myocardial infarction, ischemic stroke, and hemorrhagic stroke. Atherosclerosis. 2008. 201:130–137.

11. Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I, Ward JM, Birkedal-Hansen H. Mt1-mmp-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell. 1999. 99:81–92.

12. Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: Pathobiological mechanisms and clinical implications. Circ Res. 2006. 99:1044–1059.

13. Pollanen PJ, Lehtimaki T, Mikkelsson J, Ilveskoski E, Kunnas T, Perola M, Penttila A, Mattila KM, Nikkari ST, Syrjakoski K, Karhunen PJ. Matrix metalloproteinase3 and 9 gene promoter polymorphisms: Joint action of two loci as a risk factor for coronary artery complicated plaques. Atherosclerosis. 2005. 180:73–78.

14. Jung HH, Kim SW, Han H. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant. 2006. 21:1915–1920.

15. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001. 68:978–989.

16. Choi EK, Choi SI, Rivera JJ, Nasir K, Chang SA, Chun EJ, Kim HK, Choi DJ, Blumenthal RS, Chang HJ. Coronary computed tomography angiography as a screening tool for the detection of occult coronary artery disease in asymptomatic individuals. J Am Coll Cardiol. 2008. 52:357–365.

17. Kronmal RA, McClelland RL, Detrano R, Shea S, Lima JA, Cushman M, Bild DE, Burke GL. Risk factors for the progression of coronary artery calcification in asymptomatic subjects: Results from the multi-ethnic study of atherosclerosis (mesa). Circulation. 2007. 115:2722–2730.

18. Elkeles RS, Godsland IF, Rubens MB, Feher MD, Nugara F, Flather MD. The progress of coronary heart disease in type 2 diabetes as measured by coronary calcium score from electron beam computed tomography (ebct): The PREDICT study. Atherosclerosis. 2008. 197:777–783.

19. Wannamethee SG, Lowe GD, Rumley A, Cherry L, Whincup PH, Sattar N. Adipokines and risk of type 2 diabetes in older men. Diabetes Care. 2007. 30:1200–1205.

20. Godsland IF, Elkeles RS, Feher MD, Nugara F, Rubens MB, Richmond W, Khan M, Donovan J, Anyaoku V, Flather MD. Coronary calcification, homocysteine, c-reactive protein and the metabolic syndrome in type 2 diabetes: The prospective evaluation of diabetic ischaemic heart disease by coronary tomography (predict) study. Diabet Med. 2006. 23:1192–1200.

21. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol. 2006. 47:1850–1857.

22. Terashima M, Akita H, Kanazawa K, Inoue N, Yamada S, Ito K, Matsuda Y, Takai E, Iwai C, Kurogane H, Yoshida Y, Yokoyama M. Stromelysin promoter 5a/6a polymorphism is associated with acute myocardial infarction. Circulation. 1999. 99:2717–2719.

23. Death AK, Fisher EJ, McGrath KC, Yue DK. High glucose alters matrix metalloproteinase expression in two key vascular cells: Potential impact on atherosclerosis in diabetes. Atherosclerosis. 2003. 168:263–269.

24. Irace C, Cortese C, Migale M, Liberatoscioli L, Mannucci L, Federici G, Gnasso A. Stromelysin gene promoter polymorphism and common carotid geometry in diabetic subjects. Int Angiol. 2008. 27:413–418.